TY  - GEN
T1  - Cytobiology of Human Prostate Cancer Cells and Its Clinical Applications
A2  - Ishii, Kenichiro
LA  - eng
PB  - MDPI - Multidisciplinary Digital Publishing Institute
YR  - 2021
UL  - https://ebooks.jgu.edu.in/Record/doab-20.500.12854-68688
AB  - The number of males diagnosed with prostate cancer (PCa) is increasing all over the world. Most patients with early-stage PCa can be treated with appropriate therapy, such as radical prostatectomy or irradiation. On the other hand, androgen deprivation therapy (ADT) is the standard systemic therapy given to patients with advanced PCa. ADT induces temporary remission, but the majority of patients (approximately 60%) eventually progress to castration-resistant prostate cancer (CRPC), which is associated with a high mortality rate. Generally, well-differentiated PCa cells are androgen dependent, i.e., androgen receptor (AR) signalling regulates cell cycle and differentiation. The loss of AR signalling after ADT triggers androgen-independent outgrowth, generating poorly differentiated, uncontrollable PCa cells. Once PCa cells lose their sensitivity to ADT, effective therapies are limited. In the last few years, however, several new options for the treatment of CRPC have been approved, e.g., the CYP17 inhibitor, the AR antagonist, and the taxane. Despite this progress in the development of new drugs, there is a high medical need for optimizing the sequence and combination of approved drugs. Thus, the identification of predictive biomarkers may help in the context of personalized medicine to guide treatment decisions, improve clinical outcomes, and prevent unnecessary side effects. In this Special Issue Book, we focused on the cytobiology of human PCa cells and its clinical applications to develop a major step towards personalized medicine matched to the individual needs of patients with early-stage and advanced PCa and CRPC. We hope that this Special Issue Book attracts the attention of readers with expertise and interest in the cytobiology of PCa cells.
SN  - 9783039360345
SN  - 9783039360352
KW  - androgen receptor
KW  - docetaxel
KW  - cabazitaxel
KW  - castration-resistant prostate cancer
KW  - chemotherapy
KW  - P-glycoprotein
KW  - EPI-002
KW  - splice variant
KW  - prostate-specific antigen
KW  - androgen deprivation therapy
KW  - time to PSA nadir
KW  - fibroblasts
KW  - prostate cancer
KW  - androgen sensitivity
KW  - pirfenidone
KW  - TGFβ1
KW  - G1 cell cycle arrest
KW  - fibroblast growth factor
KW  - fibroblast growth factor receptor
KW  - obesity
KW  - inflammation
KW  - immune cells
KW  - cytokine
KW  - high-fat diet
KW  - KIFC1
KW  - docetaxel resistance
KW  - apoptosis
KW  - CW069
KW  - Caveolin-1
KW  - TP53-regulated inhibitor of apoptosis 1
KW  - tumour stroma
KW  - tumour microenvironment
KW  - fibroblast
KW  - CAF
KW  - resistance
KW  - radiotherapy
KW  - CCL2
KW  - CCL22
KW  - CCL5
KW  - migration
KW  - LSD1
KW  - epigenetics
KW  - autophagy
KW  - abiraterone
KW  - enzalutamide
KW  - testosterone
KW  - castration resistant prostate cancer
KW  - animal model
KW  - diet
KW  - fat
KW  - in vitro
KW  - in vivo
KW  - mouse
KW  - AKR1C3
KW  - hormone-naïve prostate cancer
KW  - immunohistochemistry
KW  - tissue microarray
KW  - androgen receptor dependency
KW  - fibroblast-dependent androgen receptor activation
KW  - n/a
KW  - thema EDItEUR::M Medicine and Nursing
ER  -